Cibus, Inc. Class A (CBUS)

The past six months have seen several events impacting Cibus, Inc.'s stock price, including a significant decline of 72.45% between November 2024 and November 2025, reaching a 52-week low of $1.09 in November 2025. Key events include Q1 and Q2 2025 financial results conference calls, participation in industry conferences, FDA clearance for its altered lignin alfalfa trait, a restructuring and reduction in force to focus on commercial opportunities, positive field trial results for its second-generation Herbicide Tolerance (HT2) edited Canola, a collaboration with AgVayā to introduce new solutions to Indian rice growers, the election of Craig Wichner to its Board of Directors, and Q3 2025 financial results that missed analysts' consensus estimates.

The demand for Cibus, Inc.'s products and services is inherently seasonal due to its involvement in the agricultural industry. The sale of plant and seed products is directly dependent on growing and harvesting seasons, which fluctuate annually and across different geographies. Climate change can further impact the quality, volume, and cost of seeds, as well as overall demand and product mix, thereby affecting Cibus's licensees' sales and, consequently, Cibus's royalty payments.

Cibus, Inc. is an agricultural biotechnology company specializing in gene-edited plant traits, operating within the Healthcare sector, specifically in the Biotechnology and Plant Genetics industries. Cibus utilizes its Rapid Trait Development System (RTDS®) to introduce beneficial genetic traits into various crop species, aiming to enhance crop yield, quality, and sustainability. Cibus's major products include plant traits for key agricultural crops such as Canola, Rice, Soybean, Corn, and Wheat, addressing challenges like herbicide tolerance and disease resistance. The company operates on a licensing model, developing traits and licensing them to seed companies for royalties.

Cibus has a global geographic footprint, with its traits and collaborations extending across several regions. The company has a presence in North America (including the US and Canada), Latin America (with agreements and market opportunities in countries like Uruguay, Colombia, and Brazil), Europe (with regulatory progress in the UK and EU), and Asia (including collaborations in India and general expansion efforts).

Cibus's brand reputation faced a significant challenge in the past year due to a report from Bonitas Research alleging issues with Cibus' gene-editing technology and commercialized products, leading to a stock price drop. Conversely, the FDA's completion of its Plant Biotechnology Consultation Program for Cibus's altered lignin alfalfa trait in June 2025 could be viewed as a positive development for the company's reputation.

Cibus, Inc. has a mixed ownership structure, with significant holdings by both institutional and individual (insider) investors. Major institutional owners include Fmr Llc, FDGRX - Fidelity Growth Company Fund, and Vanguard Group Inc. Major individual and insider shareholders include Sa Cellectis, Rory B. Riggs, and Jeanpierre Jules Lehmann.